338 related articles for article (PubMed ID: 34089122)
21. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
Chebib FT; Torres VE
Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics associated with 1-year tolvaptan efficacy in autosomal dominant polycystic kidney disease with a wide range of kidney functions.
Murakami T; Nishimura K; Ono H; Ueta S; Shibata E; Kishi S; Tamaki M; Miya K; Shima H; Tashiro M; Inoue T; Kawahara K; Nagai K; Abe H; Minakuchi J; Doi T
J Med Invest; 2020; 67(3.4):315-320. PubMed ID: 33148908
[TBL] [Abstract][Full Text] [Related]
23. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
Côté G; Asselin-Thompstone L; Mac-Way F; René de Cotret P; Lacroix C; Desmeules S; Agharazii M
Int Urol Nephrol; 2020 Feb; 52(2):343-349. PubMed ID: 32008201
[TBL] [Abstract][Full Text] [Related]
24. Overweight and Obesity and Progression of ADPKD.
Nowak KL; Steele C; Gitomer B; Wang W; Ouyang J; Chonchol MB
Clin J Am Soc Nephrol; 2021 Jun; 16(6):908-915. PubMed ID: 34117082
[TBL] [Abstract][Full Text] [Related]
25. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
Devuyst O; Chapman AB; Gansevoort RT; Higashihara E; Perrone RD; Torres VE; Blais JD; Zhou W; Ouyang J; Czerwiec FS
J Am Soc Nephrol; 2017 May; 28(5):1592-1602. PubMed ID: 27920153
[TBL] [Abstract][Full Text] [Related]
26. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
Blair HA
Drugs; 2019 Feb; 79(3):303-313. PubMed ID: 30689194
[TBL] [Abstract][Full Text] [Related]
27. Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression.
Furlano M; Loscos I; Martí T; Bullich G; Ayasreh N; Rius A; Roca L; Ballarín J; Ars E; Torra R
Am J Nephrol; 2018; 48(4):308-317. PubMed ID: 30347391
[TBL] [Abstract][Full Text] [Related]
28. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT
Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153
[TBL] [Abstract][Full Text] [Related]
29. Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression.
Raina R; Chakraborty R; DeCoy ME; Kline T
Pediatr Res; 2021 Mar; 89(4):894-899. PubMed ID: 32392574
[TBL] [Abstract][Full Text] [Related]
30. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
31. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Koch G; Ouyang J; McQuade RD; Blais JD; Czerwiec FS; Sergeyeva O;
N Engl J Med; 2017 Nov; 377(20):1930-1942. PubMed ID: 29105594
[TBL] [Abstract][Full Text] [Related]
32. The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.
Li X; Li W; Li Y; Dong C; Zhu P
Nefrologia (Engl Ed); 2023; 43(6):731-741. PubMed ID: 37150675
[TBL] [Abstract][Full Text] [Related]
33. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
Alpers DH; Lewis JH; Hunt CM; Freston JW; Torres VE; Li H; Wang W; Hoke ME; Roth SE; Westcott-Baker L; Estilo A
Am J Kidney Dis; 2023 Mar; 81(3):281-293.e1. PubMed ID: 36191725
[TBL] [Abstract][Full Text] [Related]
34. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease.
Mader G; Mladsi D; Sanon M; Purser M; Barnett CL; Oberdhan D; Watnick T; Seliger S
BMC Nephrol; 2022 Oct; 23(1):334. PubMed ID: 36258169
[TBL] [Abstract][Full Text] [Related]
35. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O;
Am J Nephrol; 2017; 45(3):257-266. PubMed ID: 28166521
[TBL] [Abstract][Full Text] [Related]
36. An update on tolvaptan for autosomal dominant polycystic kidney disease.
Poch E; Rodas L; Blasco M; Molina A; Quintana L
Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
[TBL] [Abstract][Full Text] [Related]
37. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
Chebib FT; Perrone RD; Chapman AB; Dahl NK; Harris PC; Mrug M; Mustafa RA; Rastogi A; Watnick T; Yu ASL; Torres VE
J Am Soc Nephrol; 2018 Oct; 29(10):2458-2470. PubMed ID: 30228150
[TBL] [Abstract][Full Text] [Related]
38. Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease.
Akihisa T; Kataoka H; Makabe S; Manabe S; Yoshida R; Ushio Y; Sato M; Tsuchiya K; Mochizuki T; Nitta K
Clin Exp Nephrol; 2022 Jun; 26(6):540-551. PubMed ID: 35165806
[TBL] [Abstract][Full Text] [Related]
39. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model.
McEwan P; Bennett Wilton H; Ong ACM; Ørskov B; Sandford R; Scolari F; Cabrera MV; Walz G; O'Reilly K; Robinson P
BMC Nephrol; 2018 Feb; 19(1):37. PubMed ID: 29439650
[TBL] [Abstract][Full Text] [Related]
40. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]